Crolius Clayton 4

What Happened

• Crolius Clayton, Chief Financial Officer of DNA X, Inc. (SONM), received a grant of 35,000 restricted stock units (RSUs) on February 9, 2026. The grant was recorded at $0.00 per unit (aggregate acquisition price $0).
• These RSUs are unvested compensation (not an open-market buy or sale) and represent the contingent right to receive one share per RSU when vested.

Key Details

• Transaction date and price: 2026-02-09; grant recorded at $0.00 per RSU.
• Shares/units reported after the transaction: beneficially owns 1,719 shares of common stock and 35,000 unvested RSUs (per filing footnote).
• Vesting: RSUs vest in equal monthly installments over one year following the grant date, subject to continued service (footnote F1).
• Reverse split note: reported amounts reflect a 1-for-18 reverse stock split effective Oct 27, 2025 (footnote F3).
• Filing timeliness: Form 4 was filed Feb 10, 2026 for the Feb 9 transaction (within the typical 2-business-day reporting window).

Context

• RSU grants are a common form of executive compensation and are not an immediate cash investment or sale; they convert to shares only as they vest. This award should be viewed as compensation, not a directional trade signal.